Trevi Therapeutics stock analysis
Want to see TRVI full AI Analyst Report?
Trevi Therapeutics (TRVI) Stock Price & Analysis
TRVI Stock Chart & Stats
- Day’s Range
- $13.27 - $14.20
- 52-Week Range
- $9.82 - $20.22
- Previous Close
- $13.51
- Volume
- N/A
- Average Volume (3M)
- 1.96M
- Market Cap
- $1.96B
- Enterprise Value
- $1.99B
- Total Cash (Recent Filing)
- $299.41M
- Total Debt (Recent Filing)
- $527.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.52
- Next Earnings
- Mar 23, 2027 (Est.)
- EPS Estimate
- -0.15
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Runway
The substantial cash position and stated runway into 2030 provide Trevi with financial capacity to advance multiple clinical programs through important data readouts. Extremely low leverage further reduces near-term financing pressure and supports continued development without relying immediately on debt.
Expanded Patent Protection
Patent protection extending to 2041 can lengthen the period in which successful Haduvio indications may be protected from direct generic competition. Additional dosing and label-related claims also strengthen the company’s ability to build an indication-specific commercial franchise.
Differentiated Clinical Positioning
Supportive regulatory alignment and an apparently uncrowded targeted chronic-cough field improve the strategic opportunity for Haduvio if clinical efficacy is confirmed. The planned expansion into non-IPF-ILD also broadens the development pathway beyond a single patient population.
Bears Say
No Revenue And Widening Losses
Trevi has no commercial revenue base and its losses are increasing as clinical development continues. Until Haduvio is approved and commercialized or partnered, the company lacks operating earnings to fund activities, making future financial performance dependent on successful development milestones.
Accelerating Cash Burn
The worsening operating cash outflow indicates that Trevi is consuming capital more quickly while still pre-revenue. Persistent negative free cash flow creates dependence on external funding over time, potentially reducing financial flexibility and increasing dilution risk if development spending remains elevated.
Future Funding Needs Remain
Although current resources cover the disclosed clinical programs, they do not cover all costs required for commercialization or certain later-stage trials. Those future expenditures could materially extend the funding requirement and create additional execution and capital-allocation pressure before revenue begins.
Trevi Therapeutics News
Trevi’s IPF Cough Trial Moves Forward as Phase 3 Study Recruits
Trevi Therapeutics ($TRVI) announced an update on their ongoing clinical study. Study Overview: Trevi Therapeutics is recruiting patients for “A Randomized, Double-Blind, Placebo-Controlled Twelve-Week Fixed-Dose Study to Evaluate the Efficacy
Trevi Therapeutics: Buy Rating Reaffirmed as Chronic-Cough Pipeline Advances; $28 Price Target Unchanged
Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Trevi Therapeutics, retaining the price target of $28.00. Debanjana Chatterjee’s rating is based on several factors, including Trevi’s progress across
Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Trevi Therapeutics, with a price target of $28.00. Debanjana Chatterjee has given his Buy rating due
Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target
Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on Trevi Therapeutics and keeping the price target at $24.00. Brandon Folkes has given his Buy rating due to a
Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged
Needham analyst Serge Belanger maintained a Buy rating on Trevi Therapeutics today and set a price target of $23.00. Serge Belanger has given his Buy rating due to a combination
TRVI FAQ
What was Trevi Therapeutics’s price range in the past 12 months?
What is Trevi Therapeutics’s market cap?
When is Trevi Therapeutics’s upcoming earnings report date?
How were Trevi Therapeutics’s earnings last quarter?
Is Trevi Therapeutics overvalued?
Does Trevi Therapeutics pay dividends?
What is Trevi Therapeutics’s EPS estimate?
How many shares outstanding does Trevi Therapeutics have?
What happened to Trevi Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Trevi Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Trevi Therapeutics Stock Smart Score
Company Description
Trevi Therapeutics
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jennifer L. Good
- Employees
- 34
- Website
- www.trevitherapeutics.com
- Address
- 195 Church Street, New Haven, CT, 06510, US
Trevi Therapeutics (TRVI) Earnings & Revenues
TRVI Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with Trevi reporting progress across its clinical programs, supportive FDA interactions, a cash runway extending into 2030, expanded patent protection, and no active competitors in its targeted chronic cough indications. The main challenges were the inherent difficulty and uncertainty of RCC development, including heterogeneity, placebo effects, possible LAKE enrollment expansion or futility, the heterogeneous non-IPF-ILD population, and unresolved RCC market-sizing questions.
View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 4 | 0 | 8 |













